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ABSTRACT 
Objective 
We aimed to determine the most efficacious of three common medication regimens for the 
sedation of acutely agitated emergency department (ED) patients.  
Methods 
We undertook a randomised, controlled, double-blind, triple-dummy, clinical trial in two 
metropolitan EDs between October 2014 and August 2015. Patients, aged 18-65 years, 
requiring intravenous (IV) medication sedation for acute agitation were enrolled and 
randomised to an IV bolus of either midazolam 5mg-droperidol 5mg, droperidol 10mg or 
olanzapine 10mg. Two top-up (additional) doses were administered, if required: midazolam 
5mg, droperidol 5mg or olanzapine 5mg, respectively. The primary outcome was the 
proportion of patients adequately sedated at ten minutes.  
Results  
349 patients were randomized to the three groups. Baseline characteristics were similar 
across the groups. Ten minutes after the first dose, significantly more patients in the 
midazolam-droperidol group were adequately sedated compared to the droperidol and 
olanzapine groups: differences in proportions (95%CI) 25.0% (12.0-38.1) and 25.4% 
(12.7-38.3), respectively. At any time point, patients in the droperidol and olanzapine groups 
were significantly less likely to be sedated compared to midazolam-droperidol patients: 
droperidol and olanzapine group hazard ratios (95%CI) were 0.53 (0.41-0.69) and 0.50 (0.39-
0.65), respectively. For times to sedation, the differences in medians (95%CI) for times to 
sedation between the midazolam-droperidol group and the droperidol and midazolam-
droperidol and olanzapine groups were 6 (3-8) and 6 (3-7) minutes, respectively. Patients in 
the midazolam-droperidol group required fewer top-up doses or alternative drugs to achieve 
adequate sedation. The three groups’ adverse event rates and lengths of stay did not differ.  
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Conclusion  
Midazolam-droperidol combination therapy is superior, in the doses studies, to either 
droperidol or olanzapine monotherapy for IV sedation of the acutely agitated ED patient.  
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INTRODUCTION 
Background  
Acute agitation among emergency department (ED) patients is often associated with 
recreational drug and/or alcohol intoxication, mental illness or combinations of diagnoses.1-5 
The agitation may escalate to violence which is disruptive and associated with a risk of injury 
to the patient and those around them.3,6 These events usually result in a ‘security code’ being 
called for an unarmed threat. De-escalation techniques are recommended initially7 although 
parenteral medication sedation may be required.3,5,6  
 
Importance 
Sedation for acute agitation is required in 3-20 cases for every 1000 ED presentations3,6 and 
the risk to the patient is real. Adverse effects are common and include airway compromise, 
oxygen desaturation, hypotension and extra-pyramidal events.3,5,8-12 The challenge is to 
employ a medication regimen that will rapidly and effectively sedate the patient without 
putting them at substantial risk of adverse events. To date, a wide range of regimens have 
been employed, mostly including benzodiazepines and/or antipsychotic medications 
administered by either the intramuscular (IM) or intravenous (IV) routes. 4,8,9,13-15  
 
Most studies of acute agitation have been undertaken in the psychiatric setting. Hence, most 
evidence is not directly applicable to the ED where the onset of sedation needs to be rapid and 
where the pathogenesis of the agitation is often undifferentiated.5 Currently, ED sedation 
guidelines are often inconsistent, poorly supported by evidence and frequently not followed.13 
Furthermore, sedation practice is evolving with new medications being incorporated into 
practice in unapproved settings or routes of administration e.g. IV olanzapine.16 
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Goals of this Investigation 
Recent research suggests that medication combination regimens are superior to 
monotherapy.1,13,15 Chan et al.1 reported that both IV midazolam-droperidol and IV 
midazolam-olanzapine combinations are superior to IV midazolam monotherapy. The 
relevance of this finding is that benzodiazepine monotherapy, especially midazolam, is 
currently the most commonly used regimen for acute agitation management in some parts of 
the world.13,15 Droperidol4,13,15 and, more recently, olanzapine4,12,16,17 are also used as 
monotherapy. To date, the efficacy of the midazolam-droperidol combination in acute 
agitation has not been compared with either droperidol or olanzapine monotherapy. We 
compared these three regimens and hypothesised that the midazolam-droperidol combination 
would be the superior regimen.  
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METHODS 
Study Design and Setting 
We undertook a randomised, controlled, double-blind, triple-dummy, clinical trial in the EDs 
of two inner city, tertiary referral, Australian hospitals with annual censuses of 45,000 and 
70,000 adult patients. Each ED is supported by 24 hour co-located psychiatric services. 
Patients were enrolled between October 2014 and August 2015, inclusive. The trial was 
registered on the Australian and New Zealand Clinical Trials Registry, (ACTRN 
ACTRN12607000591459) and approved by the Human Research Ethics Committees (HREC) 
of the participating institutions.  
 
Selection of Participants 
Patients were eligible for inclusion if they were aged 18-65 years (inclusive) and required IV 
medication sedation for acute agitation, as determined by their attending ED doctor. Patients 
were excluded if they had been previously enrolled, had a known hypersensitivity or 
contraindication to a study medication, a reversible aetiology for their agitation (hypotension, 
hypoxia, hypoglycaemia), were experiencing acute alcohol withdrawal or were pregnant.  
 
Enrolment was based upon patient and staff safety considerations and not sedation scores. 
Patients who received a sedative medication(s) within the previous 12 hours, either as usual 
medications or pre-hospital treatment, were eligible if they met other eligibility criteria. Due 
to the level of agitation, informed patient consent was not possible and HREC approval was 
given for waiver of consent.  
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Methods and Measurements 
Patients were assigned to a midazolam-droperidol combination arm, a droperidol 
monotherapy (droperidol) arm or an olanzapine monotherapy (olanzapine) arm (Figure 1). 
The first and top-up (additional) doses, respectively, were midazolam 5mg plus droperidol 
5mg and midazolam 5mg; droperidol 10mg and 5mg; olanzapine 10mg and 5mg (see Web 
Appendix). Doses were determined from clinical practice13,16,17 and previous trials1,5 and were 
administered by rapid IV push. The midazolam-droperidol combination was chosen over 
midazolam-olanzapine as droperidol is more commonly used.13,18  
 
Study packs were pre-assembled by the Pharmacy Department of a third hospital. Each 
contained a patient identification code, instructions, a case report form, vials of repackaged 
medication/placebo, water for reconstitution, normal saline for dilution, disposables, and a 
sealed envelope with a description of the vial contents (if un-blinding were required).  
 
At each site, study packs were ‘block randomised’ in groups of six (two for each study arm) to 
ensure approximately equal numbers of patients in each arm. A pharmacist not involved with 
patient enrolment, data collection or analysis, conducted the randomisation using random-
number tables and kept the codes confidential.  
 
Midazolam and droperidol are clear liquids. Olanzapine is a yellow powder that requires 
reconstitution to a yellow liquid. To achieve blinding, a ‘triple-dummy’ technique was 
employed. Normal saline was used for the clear liquid placebos. Soluvit N®, a vitamin and 
mineral preparation designed for IV parenteral nutrition, was used as the olanzapine placebo. 
Soluvit N® has been successfully employed as an olanzapine placebo.1 
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Consecutive patient enrolment was undertaken by assigning patients to the next sequential 
study pack at their site. Details of the vial contents and preparation, the administered volumes 
and doses are described in Web Appendix.  
 
If adequate sedation was not achieved within 5 minutes of the first dose, a top-up dose was 
administered. A second top-up dose was administered 5 minutes later, if required. If adequate 
sedation was not achieved 5 minutes after the second top-up dose, the ED doctor could 
administer additional, open label, sedative medication(s) at his/her discretion. At this stage, 
the doctor could un-blind the study medication(s) if this was deemed necessary for patient 
safety.  
 
Senior ED nurses recorded the level of patient sedation, and all adverse events and their 
management. Patient sedation was measured using a 6-point, validated sedation scale19 (5–
highly aroused, violent; 4–highly aroused, possibly distressed or fearful; 3–moderately 
aroused, unreasonable or hostile; 2–mildly aroused, willing to talk reasonably; 1–minimal 
agitation; 0–asleep). Scores were recorded at baseline (immediately prior to first dose 
administration) and every five minutes until 60 minutes after sedation was achieved. 
Adequate sedation was defined as a score ≤2 or when no further sedation was required, as 
determined by the treating doctor. All patients received standard sedation care including 1:1 
nursing and regular monitoring of sedation level, vital signs, cardiac rhythm and adverse 
events.  
 
 
 
 
8 
 
Outcomes 
The primary outcome was the proportion of patients adequately sedated within 10 minutes of 
the first dose administration.  
 
The secondary outcomes included time to adequate sedation, the need for re-sedation <60 
minutes after achieving sedation, re-sedation from 60 minutes after sedation until ED 
discharge, sedation medication ‘failure’ (alternate medications required), electrocardiogram 
QTc interval and adverse events.  
 
Analysis  
Chan et al.1 reported that the proportion of patients adequately sedated at 10 minutes in their 
midazolam-droperidol arm was 66.1%. We determined that a proportion less than two-thirds 
of this proportion (i.e. 44%) would represent a clinically significant difference between the 
midazolam-droperidol and either of the other arms. To demonstrate this difference in the 
proportions (66% versus 44%), at least 114 patients were required in each arm (2-sided, 
power 0.9, level of significance 0.05). Hence, a sample size of at least 342 patients was 
required.  
 
Data analysis employed the ‘Intention to Treat’ principle. Most data are presented 
descriptively, including graphically. The proportions of patients adequately sedated at 10 
minutes were analysed using differences in proportions (95% confidence intervals [95% 
CI]). Time to sedation was analysed using difference in medians (95% CI) and survival-time 
data, and was plotted using a Kaplan-Meier curve. Hazard ratios (HR, 95% CI) for adequate 
sedation were generated using the midazolam-droperidol group as a baseline reference and 
Multivariable Cox’s Regression was used to adjust for regular medications and medications 
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administered prior to the study medication. IBM SPSS Statistics for Windows (version 23, 
Armonk. NY: IBM Corp.) was used for all analyses. Un-blinding was undertaken only after all 
analyses were complete. 
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RESULTS 
Characteristics of Study Subjects 
Of 424 patients screened, 361 were enrolled (see Figure 1). An additional 12 patients were 
excluded for either missing primary endpoint data or repeat enrolment. Data from the 
remaining 349 patients (96.7% of those eligible) were analysed. The patient baseline 
characteristics are reported in Table 1. There were no significant differences between the 
groups. For these characteristics, the gross magnitude of the differences between the 
groups does not appear large enough to confound the analysis.  
 
Main Results 
Ten minutes after the first sedative dose, significantly more patients in the midazolam-
droperidol group were adequately sedated compared to the droperidol and olanzapine 
groups: differences in proportions (95%CI) 25.0% (12.0-38.1) and 25.4% (12.7-38.3), 
respectively. At each time point after the first dose, significantly fewer patients were 
adequately sedated in the droperidol and olanzapine groups: hazard ratios (95%CIs): 0.53 
(0.41-0.69) and 0.50 (0.39-0.65), respectively (Table 2, Figure 2). The Multivariable Cox 
Regression indicated that other medications had negligible impact on the hazard ratios.  
 
The median time to adequate sedation for the midazolam-droperidol group was significantly 
shorter than both the droperidol and olanzapine groups (Table 2). The difference in medians 
(95%CI) for times to sedation between the midazolam-droperidol and droperidol, and 
midazolam-droperidol and olanzapine groups were 6 (3-8) and 6 (3-7) minutes, respectively. 
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Fewer patients in the midazolam-droperidol group required top-up doses or medications other 
than top-up doses (Table 3). The groups did not differ in the proportion of patients who 
required re-sedation after initial adequate sedation had been achieved.  
 
The proportion of patients in each group who experienced an adverse event did not differ 
(Table 4). Most events were related to respiratory depression and were readily managed with 
no patient requiring endotracheal intubation.  
 
An electrocardiogram was obtained within 30 minutes of the first dose in 193 (55.3%) 
patients:  midazolam-droperidol 71 (60.2%), droperidol 61 (55.0%) and olanzapine 61 
(50.8%). The median (range) QTc intervals (msec) of the three groups were similar: 450 (325-
501), 442 (320-501) and 445 (313-501), respectively. No patient experienced a cardiac 
adverse event.  
 
There were a total of four protocol violations (Figure 1). All occurred because the patients’ 
ages were not known at the time that sedation was deemed necessary. The study age criteria 
were established for safety reasons only. The four patients were included in the data analysis 
because of our intention to treat analysis. Re-analysis of the data after their exclusion did not 
change the results.  
 
The median (IQR) ED lengths of stay (hours) for the midazolam-droperidol, droperidol and 
olanzapine groups were similar: 11.0 (7.0-14.6), 9.1 (6.2-13.3) and 10.7 (7.3-14.8), 
respectively. The groups did not differ in places of patient disposition following ED 
discharge. In each group, slightly more than one half of patients were discharged to home and 
approximately one quarter were admitted to a psychiatric ward. The remaining patients were 
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discharged to observation or medical wards, police or correctional facilities or assisted 
accommodation. Six patients absconded.  
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LIMITATIONS 
A slightly greater proportion of the midazolam-droperidol group had less urgent triage 
categories, a history of mental illness and a disposition to a psychiatry ward. However, these 
differences were minor and unlikely to have introduced confounding. Additionally, our 
analysis did not account for multiple comparisons.  
 
The sedation scale was potentially subject to measurement bias. However, the scale has been 
validated, the ED staff were fully trained in its use and it has proven reliable in our earlier 
trials.1,5 Also, any bias was likely to have been evenly distributed across all groups and 
minimised by blinding of the ED staff.  
 
Almost one half of all patients did not have an electrocardiogram recorded and this may have 
introduced selection bias. Although unlikely, it is possible that some patients with substantial 
QTc abnormalities were not identified.  
 
In this study, the first and top-up doses for each group were equivalent (total 10mg and 5mg, 
respectively). However, it was not simply assumed that the potencies at these doses would be 
equivalent. All doses were determined by careful examination of the doses commonly used in 
clinical practice13 and our earlier trials1,5. 
 
The internal validity of this study should be maximised by the use of very similar peer-
reviewed methodology.1,5 As patients were enrolled at only two centres, the external validity 
may be questionable. However, our patients are likely to be similar to those from other 
centres.   
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DISCUSSION 
This study demonstrates that, in the doses studied, a midazolam-droperidol combination is 
significantly more efficacious than droperidol or olazapine monotherapy in achieving rapid 
and adequate sedation. This is evidenced by higher proportions of patients sedated at any 
time point, shorter times to sedation, and lower proportions requiring additional sedatives 
with the combination regimen.  
 
The adverse event profiles of the three regimens did not differ although respiratory events 
were slightly more common in the midazolam-droperidol group. This is consistent with 
reports of respiratory compromise associated with midazolam sedation for both acute 
agitation1,5 and painful procedures20. Importantly, the incidence of acute dystonia was low. 
 
As the midazolam-droperidol combination in this study was identical to the midazolam-
droperidol combination of Chan et al1, the two can be compared directly. The median times 
to sedation for the two midazolam-droperidol groups were five and six minutes, respectively. 
This similarity provides strong and consistent evidence of the efficacy of this midazolam-
droperidol combination. Although the proportions of patients adequately sedated at 5 minutes 
differed (55.9% versus 35.7%, respectively), this was likely due to differences in patient 
characteristics. In particular, there were more intoxicated (drugs and/or alcohol) patients in 
the current study (48.3% versus 30.4%, respectively).  
 
The midazolam-droperidol combination has been examined previously. Chan et al.1 reported 
that the midazolam-olanzapine combination has very similar effectiveness and safety profiles. 
Although the midazolam-olanzapine combination has not been directly compared with 
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droperidol or olanzapine monotherapy, it is likely that this combination may serve as an 
effective alternative in jurisdictions where droperidol is not used.  
 
Traditionally monotherapy, administered either IV or IM, has been employed for the sedation 
of acutely agitated ED patients.4,9,13 Trials have examined benzodiazepines (midazolam, 
diazepam, lorazepam, clonazepam) 1,5,8,11,21-23, conventional antipsychotics (chlorpromazine, 
haloperidol, droperidol) 5,8,10,11,13,21-26 and atypical antipsychotics (olanzapine, ziprasidone). 
13,21,27-29 There is now increasing interest in medication combinations. The effectiveness of 
several combinations have been examined including benzodiazepine-droperidol1, 
benzodiazepine-olanzapine1,30, benzodiazepine-haloperidol8,30 and haloperidol-
promethazine11,24,28,31.  
 
While monotherapy may be simpler to administer, its mechanisms are largely limited to 
single biochemical pathways. Unfortunately, trials of medication combinations have suffered 
from uncontrolled medication re-dosing, lack of blinding and settings other than the 
ED.8,11,24,28,31 There is, however, some evidence that combinations produce more rapid 
sedation1,13,15, less need for re-sedation1 , reduced benzodiazepine dosage1 and have 
comparable adverse event profiles1. As most studies of combination therapy have used the IM 
route, comparisons with this study are difficult. To our knowledge, this is only the second 
study to have examined IV medication combinations.1   
 
Sedation with droperidol is becoming increasingly common.4,6,13 However, its widespread use 
is hindered by a ‘black box’ warning related to QTc interval prolongation.32 There is now 
increasing evidence that droperidol has a good safety profile in the ED setting.1,3,5,14,23,25 In a 
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Position Statement, Perkins et al.33 described droperidol as effective and safe. The findings of 
our trial provide additional evidence for the safety of droperidol. 
 
Olanzapine has a relatively benign side effect profile. However, a Cochrane review27 of IM 
olanzapine for acutely agitated patients concluded that published studies had poorly reported 
outcomes and the potential for bias. No trials in the ED setting were included. Subsequently, 
one ED study supported the safety of olanzapine administered by the IM route.30 Olanzapine 
is increasing being used intravenously (off label)13,16,17  and one retrospective study supports 
the safety of IV olanzapine in the ED setting.29 To date, only one clinical trial has examined 
its effects via the IV route.1 In that study, it appeared safe at the 5 mg dose and in combination 
with midazolam.1 The present study provides additional evidence that IV olanzapine is safe.   
 
Both IV and IM routes are commonly used for sedative medication administration. The IV 
and IM routes are preferred in Australasia13 and Hong Kong 15, respectively. The IV route is 
often recommended7,19,34,35 as the IM route may be unpredictable, have a slower onset and 
cannot be used for accurate titration. However, IV administration requires cannulation of the 
patient. This usually requires physical restraint which may not be an option in EDs with 
limited security or ED staff resources. To date, no published clinical trials have compared the 
effectiveness of sedatives administered by these two routes.  
 
In summary, this study demonstrates that, in the doses studied, the IV midazolam-droperidol 
combination provides significantly more rapid and effective sedation than the IV droperidol 
or olanzapine monotherapy regimens. Also, it required fewer top-up doses or other 
medications to achieve adequate sedation. It is recommended that the midazolam-droperidol 
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combination should be used for the sedation of acutely agitated ED patients regardless of 
whether or not the cause of the agitation is known.  
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Figure 1. Patient flow through the study (modified CONSORT diagram) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*patients aged 15 and 71 years 
†patients aged 68 and 69 years 
‡patient sedation difficult and un-blinding undertaken to inform clinical decision making. No un-blinding was 
undertaken in response to adverse events. 
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Figure 2. Kaplan-Meier curve comparing the proportion of patients sedated as a function of 
time. 
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Table 1. Baseline patient characteristics* 
 
 midazolam-
droperidol 
n=118 
droperidol 
 
n=111 
olanzapine 
 
n=120 
Age, years, mean (95%CI) 34 (32-36) 34 (32-36) 35 (33-37) 
Male, n (%) 72 (61.0)  68 (61.3)  69 (57.5)  
ATS category, n (%) 
    1. Resuscitation 
    2. Emergency 
    3. Urgent 
    4. Semi-urgent 
    5. Non-urgent 
 
5 (4.2) 
40 (33.9) 
69 (58.5) 
4 (3.4) 
0 (0.0) 
 
6 (5.4) 
50 (45.0) 
49 (44.1) 
6 (5.4) 
0 (0.0) 
 
9 (7.5) 
50 (41.7) 
56 (46.7) 
5 (4.2) 
0 (0.0) 
Waiting time from triage to be seen by a 
doctor, minutes, median (IQR) 
23 (4-53) 12 (4-31) 21 (3-44) 
ICD-10 category, n (%) 
    Intoxication (drugs and/or alcohol) 
    Mental illness† 
    Organic illness‡ 
 
57 (48.3) 
56 (47.5) 
5 (4.2) 
 
61 (55.0) 
45 (40.5) 
5 (4.5) 
 
65 (54.2) 
47 (39.2) 
8 (6.6) 
Substance abuse history§, n (%) 95 (80.5) 103 (92.8) 100 (83.3) 
Usual psychotropic medications, n (%) 
    Benzodiazepines 
    SSRI or SNRI 
    Atypical antipsychotics 
    Depot antipsychotics 
    Conventional antipsychotics 
33 (28.0) 
8 (6.8)  
6 (5.1) 
10 (8.5) 
2 (1.7) 
5 (4.2) 
29 (26.1) 
4 (3.6) 
7 (6.3) 
14 (12.6) 
4 (3.6) 
3 (2.7) 
34 (28.3) 
6 (5.0) 
7 (5.8) 
18 (15.0) 
3 (2.5) 
3 (2.5) 
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Need for physical restraint, n (%) 85 (72.0) 86 (77.5) 93 (77.5) 
Sedatives prior to enrolment¶, n (%) 32 (27.1) 30 (27.0) 26 (21.7) 
Police attendance on arrival, n (%) 80 (67.8) 78 (70.3) 93 (77.5) 
Mode of arrival, n (%) 
    Road ambulance 
    Police 
    Other¥ 
 
69 (58.5) 
41 (34.8) 
8 (6.7) 
 
67 (60.4) 
37 (33.3) 
7 (6.3) 
 
69 (57.5) 
42 (35.0) 
9 (7.5) 
 
ATS, Australasian Triage Scale; IQR, Interquartile Range; ICD-10, International Classification of Diseases, 10th 
Revision; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin noradrenaline reuptake inhibitor. 
†Mental illness includes psychoses, anxiety, depressive illnesses and trauma as a consequence of suicide 
attempt; ‡Organic illness includes infections, delirium due to an organic cause and all other trauma; §Substances 
include drugs and/or alcohol; ¶Sedatives (i.e. benzodiazepines and antipsychotics) prior to study enrolment 
include those administered in the pre-hospital care setting (i.e. administered by paramedics) or when in the ED; 
¥Other modes of transport include private travel (i.e. self, family, friends). 
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Table 2. Primary Endpoints: Proportions of patients sedated at specific time points after first 
dose administration and median times to adequate sedation 
 
 midazolam-
droperidol 
n=118 
droperidol  
 
n=111 
olanzapine 
 
n=120 
    
Proportion sedated, n (%) 
    at 5 minutes 
    at 10 minutes 
    at 15 minutes 
    at 30 minutes 
    at 60 minutes 
 
66 (55.9) 
88 (74.6) 
105 (89.0) 
113 (95.8) 
116 (98.3) 
 
27 (24.3) 
55 (49.6) 
67 (60.4) 
92 (82.9) 
106 (95.5) 
 
35 (29.2) 
59 (49.2) 
79 (65.8) 
96 (80.0) 
109 (90.8) 
Time to sedation, mins, median (IQR) 5 (3-11) 11 (6-23) 11 (5-25) 
 
 
IQR inter-quartile range 
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Table 3. Secondary endpoints, the need for addition parenteral sedative medication (patients 
may be administered more than one medication) 
 
 midazolam
-droperidol 
n=118 
droperidol 
 
n=111 
olanzapine 
 
n=120 
Number of top-up doses required to reach 
initial adequate sedation, n (%) 
    0 
    1 
    2 
 
 
85 (72.0) 
25 (21.2) 
8 (6.8) 
 
 
45 (40.5) 
30 (27.0) 
36 (32.4) 
 
 
47 (39.2) 
29 (24.2) 
44 (36.7) 
 
Need for additional parenteral medications to 
reach initial adequate sedation*, n (%) 
    midazolam 
    droperidol 
    olanzapine 
    ketamine 
 
2 (1.7) 
 
2 (1.7) 
0 (0.0) 
2 (1.7) 
0 (0.0) 
 
15 (13.5) 
 
12 (10.8) 
5 (4.5) 
1 (0.9) 
1 (0.9) 
 
31 (25.8) 
 
27 (22.5) 
9 (7.5) 
8 (6.7) 
0 (0.0) 
 
Need for additional parenteral re-sedation <60 
minutes after initial adequate sedation, n (%) 
    midazolam 
    droperidol 
    olanzapine 
    ketamine 
 
7 (5.9) 
 
5 (4.2) 
3 (2.5) 
3 (2.5) 
0 (0.0) 
 
5 (4.5) 
 
3 (2.7) 
2 (1.8) 
1 (0.9) 
1 (0.9) 
 
10 (8.3) 
 
8 (6.7) 
3 (2.5) 
4 (3.3) 
0 (0.0) 
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Need for additional parenteral re-sedation from 
60 minutes after initial adequate sedation, until 
ED discharge, n (%) 
    midazolam 
    droperidol 
    olanzapine 
    ketamine 
 
26 (22.0) 
 
18 (15.3) 
14 (11.9) 
8 (6.8) 
0 (0.0) 
 
16 (14.4) 
 
12 (10.8) 
4 (3.6) 
4 (3.6) 
1 (0.9) 
 
28 (23.3) 
 
23 (19.2) 
9 (7.5) 
9 (7.5) 
1 (0.8) 
 
 
*additional parenteral sedatives include medication doses required in addition to the study medication top-up 
doses. 
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Table 4. Reported adverse events 
 
 midazolam-
droperidol 
n=118 
droperidol 
 
n=111 
olanzapine 
 
n=120 
Number of patients with reported events, n (%)* 26 (22.0) 18 (16.2) 24 (20.0) 
    airway obstruction† 
    oxygen desaturation† (SaO2 <90%) 
    hypotension‡ (SBP <80 mmHg) 
    bradycardia (HR <60 beats/min) 
    prolonged QTc§ (QTc interval >500ms) 
    acute dystonia¶ 
    hypoventilation (RR <10 breaths/min) 
11 (9.3) 
17 (14.4) 
2 (1.7) 
0 (0.0) 
1 (0.8) 
1 (0.8) 
0 (0.0) 
4 (3.6) 
7 (6.3) 
4 (3.6) 
2 (1.8) 
3 (2.7) 
0 (0.0) 
1 (0.9) 
5 (4.2) 
13 (10.8) 
1 (0.8) 
5 (4.2) 
3 (2.5) 
2 (1.7) 
1 (0.8) 
 
 
SaO2 arterial oxygen saturation, SBP systolic blood pressure, HR heart rate, RR respiratory rate 
*Patients may have experienced more than one event; †All cases of airway obstruction and oxygen desaturation 
were transient and resolved with jaw thrust, lateral positioning, with or without supplemental oxygen; ‡All cases 
resolved after the administration of fluids, without sequelae; §No clinical symptoms and no treatment was 
required for all cases of prolonged QTc; ¶All cases resolved without sequelae, one case in the olanzapine group 
required benztropine 
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Web Appendix - Medication Vial Preparation and Dosage Regimen 
 
Medication vial preparation: 
 
After enrolment, the two clear liquid vials (A and B) were drawn up and the yellow powder 
vial (C) was reconstituted and drawn up. The first dose of sedative(s) comprised contents 
from all three vials (two clear and one yellow liquid). Top-up doses, if required, comprised 
contents from two vials only (one clear and one yellow liquid).  
 
 
Medication regimen: 
 
1. Midazolam-droperidol combination (control) arm: 
           Vial A        Vial B             Vial C 
 midazolam 
(15mg/15ml) 
(clear solution) 
droperidol 
(5mg/2ml) 
(clear solution) 
placebo 
2 x (10ml) 
(yellow solution) 
First dose 5mg (5ml) 5mg (2ml) 0mg (10ml) 
1st top-up dose 
(if required) 
5mg (5ml) no dose 0mg (5ml) 
2nd top-up dose 
(if required) 
5mg (5ml) no dose 0mg (5ml) 
NB. minimum (maximum) total dose: midazolam 5mg (15mg), droperidol 5mg (5mg) 
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2. Droperidol monotherapy (droperidol) arm: 
        Vial A        Vial B             Vial C 
 
 
droperidol 
(15mg/15ml) 
(clear solution) 
droperidol 
(5mg/2ml) 
(clear solution) 
placebo 
2 x (10ml) 
(yellow solution) 
First dose 5mg (5ml) 5mg (2ml) 0mg (10ml) 
1st top-up dose 
(if required) 
5mg (5ml) no dose 0mg (5ml) 
2nd top-up dose 
(if required) 
5mg (5ml) no dose 0mg (5ml) 
NB. minimum (maximum) total dose:  droperidol 10mg (20mg) 
 
3. Olanzapine monotherapy (olanzapine) arm: 
        Vial A         Vial B            Vial C 
 placebo 
(15ml) 
(clear solution) 
placebo 
(2ml) 
(clear solution) 
olanzapine 
2 x (10mg/10ml) 
(yellow solution) 
First-dose 0mg (5ml) 0mg (2ml) 10mg (10 ml) 
1st top-up dose 
(if required) 
0mg (5ml) no dose 5mg (5ml) 
2nd top-up dose 
(if required) 
0mg (5ml) no dose 5mg (5ml) 
NB. minimum (maximum) dose:  olanzapine 10mg (20mg) 
 
 
